Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-week open-label extension of SPT-300 monotherapy in adults with major depressive disorder
2025-522347-18-00Phase 2Authorised
- Sponsor
- Seaport Therapeutics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of brexanolone in major depressive disorder (MDD), sponsored by Seaport Therapeutics. Primary endpoints: Safety and tolerability and Suicidal ideation and behavior. Planned start Nov 2025; status: authorised.
02
Drugs
brexanolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-522347-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522347-18-00.